Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and Waters Corporation (NYSE: WAT), a global life sciences and diagnostics leader, today announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp's nationwide laboratory network beginning in late 2026.